Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Ph 3 Trial of Novel Telomere-Targeting Anticancer Therapy April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing for Global Development of Solid Tumor CAR-T Therapies April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Novel ADC Payload Targeting RNA Splicing April 7, 2026
Stipple Bio Launches with $100M Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline April 7, 2026
OnKure Therapeutics Announces Oversubscribed $150M Private Placement to Advance Two PI3Kα Pan-Mutant Selective Inhibitors in Breast Cancer and Vascular Anomalies April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer April 7, 2026
Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs March 24, 2026
Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818 for HR+/HER2- breast cancer and other solid tumor indications March 24, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC March 24, 2026
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies March 24, 2026
